Idera Pharmaceuticals, Inc.
IDRA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | 0.00 |
| FCF Yield | -2,149.44% | -1,388.13% | -462.76% | -1,456.55% |
| EV / EBITDA | 0.37 | -0.31 | 0.22 | 0.64 |
| Quality | ||||
| ROIC | -27.40% | -91.59% | -103.16% | 588.13% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 1.05 | -0.25 | 0.30 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 17.09% |
| Free Cash Flow Growth | 0.41% | 27.18% | 24.11% | 14.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | -0.32 | 0.29 | 0.69 |
| Interest Coverage | -136.36 | -3,953.29 | -12,229.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |